In addition, diagnostic yield in relation to form, location of the varices, grade, and extent of PHG was evaluated. EVs were found by EGD in 71 patients. The overall diagnostic yield of CE for EVs was 72% (51/71). The diagnostic yield was significantly greater for F2/F3 EVs than for F1 EVs (87% vs 61%, P = 0.03). The diagnostic yield was significantly greater AP24534 in vivo for Lm/Ls EVs than for Li EVs (85% vs 55%, P = 0.01). The diagnostic yield was significantly

greater for locus superior/locus medialis EVs than for locus inferior EVs (85% vs 55%, P = 0.01). GVs were found by EGD in 29 patients. Only one case was detected by CE. PHG was found by EGD in 35 patients. The diagnostic yield of CE for PHG www.selleckchem.com/products/RO4929097.html was 69% (24/35). There was no difference in diagnostic yield between cases of severe and mild PHG (82% vs 63%, P = 0.44). Diagnostic yield of CE

for PHG in the gastric body was significantly greater than that in the fundus (100% vs 48%, P = 0.0009). CE is reliable for diagnosis of F2/F3 and/or Lm/Ls EVs and of PHG in the gastric body. “
“G PUNCH,1,2 S NEWMAN,1 C DUNCAN,1 R WARNER,1,2 S WHITE1,2 1Department of General Surgery, The Tweed Hospital, Tweed Heads, NSW, Australia, 2John Flynn Colorectal Centre, John Flynn Private Hospital, Tugun, QLD, Australia Background: Botulinum toxin A is considered an effective and safe first line interventional therapy for the treatment of chronic anal fissure (CAF). Success rates for treatment with botulinum toxin A have been proven to be dose dependent. No check details data examining the safety and efficacy of routine high dose botulinum toxin A is currently available. Aim: The primary outcome of this study

was the safety (side effect profile) of high dose botulinum toxin A (80–100 IU) in the treatment of CAF, with secondary outcomes of efficacy and patient satisfaction. Method: Retrospective analysis of 80 patients treated with botulinum toxin A at a single colorectal unit between 2009 and 2013. Follow up was performed at post-operative consultation and through further phone contact regarding side effects, recurrence of symptoms and satisfaction. Minimum follow up ranged from six months to five years. Between 2009–2011, 58 patients were treated with low dose botulinum toxin A (mean dose 51.2 IU). Between 2012–2013, 22 patients were treated with high dose botulinum toxin A (mean dose 82.1 IU). Data collated was analysed using Chi Squared Test to assess for significant differences between the low and high dose groups. Results: There was no statistically significant difference between the low dose and high dose treatment groups in the side effect profile, bleeding (3.4% vs. 4.5% respectively), incontinence of flatus (3.4% vs. 4.5%) and incontinence of stool (3.4% vs. 4.5%). Pain from CAF following treatment was significantly less in the high dose group (0.0%) compared to the low dose group (15.5%, P < 0.05). Overall, 89.